indication

Mental Disorders

Competitive landscape projected to transcranial Direct Current Stimulation tDCS’s launch window

as of 2026-07-01
Competitive set
14
12 approved · 2 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
115 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
today
transcranial Direct Current Stimulation tDCS launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Risperidone
US-approved 1993 · RISPERDAL
Phase 412 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 37 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 46 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 34 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 44 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Cariprazine (Vraylar)
US-approved 2015 · Vraylar
Phase 33 trials
OwnerForest Laboratories
Protection2030
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 31 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 31 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Iloperidone
US-approved 2009 · FANAPT
Phase 31 trial
OwnerVanda Pharmaceuticals
Protection2031
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 21 trial
OwnerSumitomo Pharmaceuticals America
Protection2031
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugCompleted
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 31 trial
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugCompleted
Emraclidine
Pipeline · Phase 2
Phase 24 trials
OwnerCerevel Therapeutics, LLC
Protection—
drugUnknown
Minocycline
Pipeline · Phase 1
Phase 11 trial
OwnerShalvata Mental Health Center
Protection—

Market size

prevalence as a range, not a number